卡介苗（BCG）暴露和卡介苗无反应定义的光与影：实用概述。

IF 8.3 1区医学 Q1 ONCOLOGY

European urology oncology Pub Date : 2024-09-26 DOI:10.1016/j.euo.2024.09.010

Luca Afferi, Andrea Gallioli, Damiano Stracci, Agostino Mattei, Christian Fankhauser, Marco Moschini, Peter C Black, Benjamin Pradere, Jorge Huguet Pérez, Oscar Rodriguez-Faba, Joan Palou, Alberto Breda

{"title":"卡介苗（BCG）暴露和卡介苗无反应定义的光与影：实用概述。","authors":"Luca Afferi, Andrea Gallioli, Damiano Stracci, Agostino Mattei, Christian Fankhauser, Marco Moschini, Peter C Black, Benjamin Pradere, Jorge Huguet Pérez, Oscar Rodriguez-Faba, Joan Palou, Alberto Breda","doi":"10.1016/j.euo.2024.09.010","DOIUrl":null,"url":null,"abstract":"According to the current definitions of recurrence of non-muscle-invasive bladder cancer after bacillus Calmette-Guérin (BCG), patients in the BCG-exposed and late relapse categories might benefit from further instillations. Patients with BCG-unresponsive disease could be included in clinical trials, but otherwise radical cystectomy is the preferred treatment. BCG-intolerant disease still represents an area of debate, with limited evidence regarding the best treatment for these patients.","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lights and Shadows of Bacillus Calmette-Guérin (BCG)-exposed and BCG-unresponsive Definitions: A Practical Overview.\",\"authors\":\"Luca Afferi, Andrea Gallioli, Damiano Stracci, Agostino Mattei, Christian Fankhauser, Marco Moschini, Peter C Black, Benjamin Pradere, Jorge Huguet Pérez, Oscar Rodriguez-Faba, Joan Palou, Alberto Breda\",\"doi\":\"10.1016/j.euo.2024.09.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"According to the current definitions of recurrence of non-muscle-invasive bladder cancer after bacillus Calmette-Guérin (BCG), patients in the BCG-exposed and late relapse categories might benefit from further instillations. Patients with BCG-unresponsive disease could be included in clinical trials, but otherwise radical cystectomy is the preferred treatment. BCG-intolerant disease still represents an area of debate, with limited evidence regarding the best treatment for these patients.\",\"PeriodicalId\":12256,\"journal\":{\"name\":\"European urology oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":8.3000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euo.2024.09.010\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euo.2024.09.010","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

根据目前对卡介苗（BCG）治疗后非肌层浸润性膀胱癌复发的定义，卡介苗暴露和晚期复发类别的患者可能会从进一步灌注中获益。对卡介苗无反应的患者可参加临床试验，但除此之外，根治性膀胱切除术是首选治疗方法。卡介苗不耐受的疾病仍是一个争论不休的领域，有关这些患者最佳治疗方法的证据有限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Lights and Shadows of Bacillus Calmette-Guérin (BCG)-exposed and BCG-unresponsive Definitions: A Practical Overview.

According to the current definitions of recurrence of non-muscle-invasive bladder cancer after bacillus Calmette-Guérin (BCG), patients in the BCG-exposed and late relapse categories might benefit from further instillations. Patients with BCG-unresponsive disease could be included in clinical trials, but otherwise radical cystectomy is the preferred treatment. BCG-intolerant disease still represents an area of debate, with limited evidence regarding the best treatment for these patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European urology oncology Multiple-

CiteScore

15.50

自引率

2.40%

发文量

128

审稿时长

20 days

期刊介绍： Journal Name: European Urology Oncology Affiliation: Official Journal of the European Association of Urology Focus: First official publication of the EAU fully devoted to the study of genitourinary malignancies Aims to deliver high-quality research Content: Includes original articles, opinion piece editorials, and invited reviews Covers clinical, basic, and translational research Publication Frequency: Six times a year in electronic format